Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GABRIEL LOPEZ and ROBERT COLEMAN.
GABRIEL LOPEZ
Connection Strength
0.692
ROBERT COLEMAN
  1. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85.
    View in: PubMed
    Score: 0.099
  2. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99.
    View in: PubMed
    Score: 0.094
  3. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
    View in: PubMed
    Score: 0.093
  4. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.
    View in: PubMed
    Score: 0.072
  5. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.
    View in: PubMed
    Score: 0.030
  6. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.030
  7. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.
    View in: PubMed
    Score: 0.030
  8. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.
    View in: PubMed
    Score: 0.027
  9. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
    View in: PubMed
    Score: 0.025
  10. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9.
    View in: PubMed
    Score: 0.025
  11. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67.
    View in: PubMed
    Score: 0.024
  12. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.
    View in: PubMed
    Score: 0.023
  13. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
    View in: PubMed
    Score: 0.021
  14. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
    View in: PubMed
    Score: 0.021
  15. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
    View in: PubMed
    Score: 0.021
  16. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.
    View in: PubMed
    Score: 0.020
  17. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.
    View in: PubMed
    Score: 0.018
  18. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.